|
FDA Prodded to Push Bio-Innovation; Agency Eyes ‘Science Enclaves’
To boost biopharma innovation and U.S. competition in the sector, the FDA should incentivize precompetitive industry collaborations, promote public-private partnerships and wrap up integration of its information technology (IT) systems, a new Obama administration paper states.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives